Fig. 2

Network graphs of eligible trials assessing front-line treatments in newly diagnosed CP-CML for six outcomes. (a) MMR within 12 months; (b) CCyR within 12 months; (c) Progression to AP-CML; (d) Serious AEs; (e) Overall discontinuation; (f) Discontinuation for drug-related AEs